Bristol-Myers Squibb

by Investor's Business Daily, Benzinga Contributor
June 22, 2011 7:19 PM | 9 seconds read |
Bristol-Myers Squibb (BMY) and Pfizer (PFE) said their blood-thinner candidate drug Eliquis met the goals of a phase 3 trial. Bristol-Myers was up 6%. Pfizer climbed 3%.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Health CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!